Health
Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19) – News-Medical.Net
Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to…
Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.
The team’s SARS-BLOCK™ peptides competitively inhibit the receptor-binding domain (RBD) on the SARS-CoV-2 spike protein – the surface structure that binds the host cell angiotensin-converting enzyme 2 (ACE2) receptor, to…
-
Business5 hours agoSoaring one day, plunging the next. Why is the ASX 200 on a rollercoaster?
-
Business12 hours agoHow I’d build a $100,000 ASX portfolio from scratch
-
Noosa News7 hours agoBrisbane man Benjamin Holt speaks out about teen who allegedly organised Airbnb party that led to his house being trashed
-
General17 hours agoVolodymyr Zelenskyy claims Chinese soldiers fighting alongside Russians in Ukraine